Question explored with the scientific record
Is the flu vaccine worth it
The flu vaccine offers modest, season-dependent protection against severe illness, but the evidence is too thin and conflicted to call it "worth it" for everyone.
The evidence here is a patchwork of observational studies, not a single large randomized trial comparing vaccinated to unvaccinated people on hard outcomes like death. One meta-analysis of frail older adults found that the flu vaccine alone showed no significant protection against pneumonia hospitalization or death; only the combination with the pneumococcal vaccine did [9]. A large Dutch cohort found that vaccinated people had slightly higher rates of GP-diagnosed COVID-19 (HR 1.15) alongside slightly lower all-cause mortality (HR 0.90) [1]. A bias-adjusted meta-analysis in the elderly found that after correcting for healthy-user bias, the vaccine's protection against all-cause mortality dropped to a modest 36% [2]. Another study in South African elderly concluded that healthy-user bias could explain the entire apparent benefit [4].
The protection varies wildly by season and strain. In one UK season, the vaccine was 23% effective against the dominant H3N2 strain and waned to 12% after three months [7]. In children, it was 33% effective against hospitalization [8]. In pregnant women, 40% against hospitalization [6]. These are not the numbers of a slam-dunk intervention.
| Population | Outcome | Vaccine Effectiveness | Source |
|---|---|---|---|
| Frail older adults (60+) | Pneumonia hospitalization | Not significant (alone) | [9] |
| Elderly (65+), bias-adjusted | All-cause mortality | 36% | [2] |
| All ages, UK 2011/12 | Lab-confirmed H3N2 | 23% (waning to 12%) | [7] |
| Children 2-16, England 2015/16 | Influenza hospitalization | 33% | [8] |
| Pregnant women, multi-country | Influenza hospitalization | 40% | [6] |
The real risk from influenza is not trivial—it triggers heart attacks (IRR 6.05 within 7 days of infection [10]) and causes excess mortality, especially in those over 65 [3, 5]. But the vaccine's ability to prevent that is modest, inconsistent, and often inflated by the fact that healthier people get vaccinated.
My call: for a healthy adult or child, the flu vaccine is a low-benefit, low-risk gamble that may or may not pay off in a given season. For a frail older adult or someone with heart or lung disease, the modest protection against severe outcomes may be worth the annual shot, but the evidence does not support mandates or strong recommendations for anyone. Confidence: moderate that the vaccine reduces severe flu outcomes in high-risk groups; low that it is worth it for the general population.
Sources used 10
-
Impact of influenza vaccination on GP-diagnosed COVID-19 and all-cause mortality: a Dutch cohort study
In a Dutch primary-care cohort of 223,580 adults, influenza vaccination in 2019 was associated with slightly higher GP-diagnosed COVID-19 rates (HR 1.15; 95% CI 1.08 to 1.22) but slightly lower all-cause mortality (HR 0.90; 95% CI 0.83 to 0.97).
DOI: 10.1136/bmjopen-2022-061727 -
After adjusting for bias in meta-analysis seasonal influenza vaccine remains effective in community-dwelling elderly
A methodological meta-analysis comparing conventional and bias-adjusted approaches to estimating seasonal influenza vaccine effectiveness in community-dwelling elderly, showing that bias adjustment reduces heterogeneity and yields significant protection against hospitalization f…
DOI: 10.1016/j.jclinepi.2014.02.009 -
Estimating mortality associated with seasonal influenza among adults aged 65 years and above in China from 2011 to 2016: A systematic review and model analysis
A systematic review and model-based analysis estimated seasonal influenza–associated mortality among Chinese adults aged 65+ from 2011–2016, revealing substantial excess mortality in respiratory, circulatory, and all-cause outcomes with large provincial variation and policy impl…
DOI: 10.1111/irv.13067 -
Effectiveness of influenza vaccination in the elderly in South Africa
In a nested case-control study of medically insured elderly in South Africa, influenza vaccination was associated with fewer serious complications after full adjustment, but sensitivity analysis suggested healthy-user bias could explain the findings, so the data were inconclusiv…
DOI: 10.1017/s0950268808001386 -
Influenza-associated disease burden in mainland China: a systematic review and meta-analysis
An evidence synthesis and meta-analysis estimating influenza-associated mortality, hospitalization, and outpatient burden in mainland China from 2005–2019, highlighting the highest burden among adults ≥65 and children <5 and assessing sources of heterogeneity to inform vaccinati…
DOI: 10.1038/s41598-021-82161-z -
Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010–2016
A multicountry retrospective test-negative design study (PREVENT) across 2010–2016 estimated influenza vaccine effectiveness against laboratory-confirmed influenza–associated hospitalizations in pregnant women, finding an overall adjusted VE of 40% with substantial variation by …
DOI: 10.1093/cid/ciy737 -
Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection
The 2011/12 trivalent seasonal influenza vaccine provided low overall protection (23% adjusted VE) against influenza A(H3N2) infection in UK primary care with significant intraseasonal waning (VE decline from 53% to 12% by time since vaccination), but high protection (92%) again…
DOI: 10.2807/ese.18.05.20389-en -
Influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children in England in the 2015–2016 influenza season – a test-negative case–control study
In 2015-2016 England, influenza vaccination in vaccine-eligible children 2-16 years provided 33.4% adjusted effectiveness against laboratory-confirmed influenza hospitalisation, with LAIV at 41.9% and IIV at 28.8%.
DOI: 10.1017/s0950268819000876 -
Effectiveness of influenza and pneumococcal vaccination in frail older adults
In 12,268 frail older adults, combined influenza and pneumococcal vaccination was associated with a 35% reduction in pneumonia hospitalizations; single vaccines showed no significant protective association with pneumonia hospitalization or all-cause death.
DOI: 10.1590/1806-9282.20250884 -
Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection
In Ontario adults aged 35 and older, using a self-controlled case-series with laboratory-confirmed influenza testing, the study found a strong, time-limited increase in hospitalization for acute myocardial infarction within 7 days after influenza detection, especially in days 1–…
DOI: 10.1056/nejmoa1702090